(19.) Chen WH, Lee PY, Ng W, Tse HF, Lau CP
Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.
New research also shows that
Aspirin is very useful in colorectal cancer but still we need more research and one has to be extremely careful while treating elderly patients.
Early this March, however, the American College of Cardiology and the American Heart Association issued new guidelines, which stated among other things that daily low-dose
aspirin is no longer recommended as a preventative for older adults who don't have a high risk for, or existing, heart disease.
In this issue of JFP, Smith and colleagues summarize the 2016 recommendations of the US Preventive Services Task Force (USPSTF) regarding
aspirin for primary prevention, as well as the 4 large
aspirin prevention trials published in 2018 subsequent to the USPSTF recommendations.
"In general, the practice of using
aspirin in all comers with the hopes that it will prevent a heart attack or stroke is poor practice, especially given this recent data," says Haitham Ahmed, MD, with Cleveland Clinic's Section of Preventive Cardiology and Cardiac Rehabilitation.
In the ARRIVE study, which involved 13,000 patients at moderate cardiovascular risk, daily
aspirin had no effect on rates of death or heart attack, but increased the risk of gastrointestinal bleeding.
"When we first discovered that
aspirin could reduce heart attacks doctors started prescribing it - and people started taking it off their own backs - in large numbers.
The
aspirin takers were also 38 percent more likely to suffer a "major hemorrhage" such as stomach or brain bleeding serious enough to require transfusion, hospitalization, or surgery.
Taking low-dose
aspirin regularly, however, is not right for everyone.
But anti-inflammatory medications, such as
aspirin, have been shown to lower the risk of certain types of cancers.
Here are some key points about
aspirin. More detail is in the main article.
There's more: The National Cancer Institute suggests that low-dose
aspirin may decrease the risk of colorectal cancer.
A large, randomized trial concluded that 21 percent of diabetes patients who qualified for
aspirin therapy for cardiovascular risk reduction were not getting it, and that it was contraindicated in almost 60 percent of those who were taking it, reported at the meeting.
Our objective was to determine the effect and influence of early
aspirin therapy on fatal and nonfatal bleeding complications and blood requirements after coronary bypass surgery (CABG).
